{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:00:33Z","timestamp":1790892033816,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s13318-022-00770-z","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T14:08:37Z","timestamp":1653487717000},"page":"549-559","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Results From Phase I Studies Investigating the Dose Linearity of Finerenone Tablets and the Influence of Food or pH-Modifying Comedications on its Pharmacokinetics in Healthy Male Volunteers"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4645-5428","authenticated-orcid":false,"given":"Roland","family":"Heinig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Nagelschmitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Loewen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"770_CR1","doi-asserted-by":"crossref","unstructured":"Kolkhof P, B\u00e4rfacker L. 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234(1):T125\u201340.","DOI":"10.1530\/JOE-16-0600"},{"key":"770_CR2","doi-asserted-by":"crossref","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM, Mineralocorticoid Receptor Antagonist Tolerability Study\u2013Diabetic Nephropathy Study Group. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314(9):884\u201394.","DOI":"10.1001\/jama.2015.10081"},{"issue":"31","key":"770_CR3","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P, Gheorghiade M, Filippatos G, Krum H, Nowack C, Kolkhof P, Kim SY, Zannad F. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J. 2013;34(31):2453\u201363.","journal-title":"Eur Heart J"},{"issue":"23","key":"770_CR4","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"key":"770_CR5","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"770_CR6","doi-asserted-by":"crossref","unstructured":"Frampton JE. Finerenone: first approval. Drugs. 2021;81(15):1787\u201394.","DOI":"10.1007\/s40265-021-01599-7"},{"key":"770_CR7","doi-asserted-by":"crossref","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone\u2014results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016;30(2):172\u201384.","DOI":"10.1111\/fcp.12170"},{"key":"770_CR8","doi-asserted-by":"crossref","unstructured":"Heinig R, Gerisch M, Engelen A, Nagelschmitz J, Loewen S. Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug\u2013drug interaction studies in vitro and in vivo. Eur J Drug Metab Pharmacokinet. 2018;43(6):715\u201327.","DOI":"10.1007\/s13318-018-0483-9"},{"issue":"11","key":"770_CR9","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1124\/dmd.118.083337","volume":"46","author":"M Gerisch","year":"2018","unstructured":"Gerisch M, Heinig R, Engelen A, Lang D, Kolkhof P, Radtke M, Platzek J, Lovis K, Rohde G, Schwarz T. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metab Dispos. 2018;46(11):1546\u201355.","journal-title":"Drug Metab Dispos"},{"key":"770_CR10","doi-asserted-by":"crossref","unstructured":"Heinig R, Gerisch M, Bairlein M, Nagelschmitz J, Loewen S. Results from drug\u2013drug interaction studies in vitro and in vivo investigating the effect of finerenone on the pharmacokinetics of comedications. Eur J Drug Metab Pharmacokinet. 2020;45(4):433\u201344.","DOI":"10.1007\/s13318-020-00610-y"},{"issue":"6","key":"770_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/cpdd.263","volume":"5","author":"R Heinig","year":"2016","unstructured":"Heinig R, Kimmeskamp-Kirschbaum N, Halabi A, Lentini S. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with renal impairment. Clin Pharmacol Drug Dev. 2016;5(6):488\u2013501.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"770_CR12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s13318-019-00547-x","volume":"44","author":"R Heinig","year":"2019","unstructured":"Heinig R, Lambelet M, Nagelschmitz J, Alatrach A, Halabi A. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94\u20138862) in individuals with mild or moderate hepatic impairment. Eur J Drug Metab Pharmacokinet. 2019;44(5):619\u201328.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"770_CR13","doi-asserted-by":"crossref","unstructured":"Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet. 2020;59(3):359\u201370.","DOI":"10.1007\/s40262-019-00820-x"},{"key":"770_CR14","doi-asserted-by":"publisher","unstructured":"van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R, Joseph A, Garmann D, Lippert J, Eissing T. Finerenone dose-exposure-response for the primary kidney outcome in FIDELIO-DKD phase III: population pharmacokinetic and time-to-event analysis. Clin Pharmacokinet. 2021. https:\/\/doi.org\/10.1007\/s40262-021-01082-2.","DOI":"10.1007\/s40262-021-01082-2"},{"key":"770_CR15","doi-asserted-by":"publisher","first-page":"122643","DOI":"10.1016\/j.jchromb.2021.122643","volume":"1172","author":"G Rohde","year":"2021","unstructured":"Rohde G, Loewen S, Heinig R. Determination of finerenone\u2014a novel, selective, nonsteroidal mineralocorticoid receptor antagonist\u2014in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in venous and capillary human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2021;1172:122643.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"10","key":"770_CR16","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1023\/A:1026451721686","volume":"17","author":"BP Smith","year":"2000","unstructured":"Smith BP, Vandenhende FR, DeSante KA, Farid NA, Welch PA, Callaghan JT, Forgue ST. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17(10):1278\u201383.","journal-title":"Pharm Res"},{"key":"770_CR17","unstructured":"US Department of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research (CDER). Guidance for industry. Food-effect bioavailability and fed bioequivalence studies, December 2002. 2002. https:\/\/www.fda.gov\/files\/drugs\/published\/Food-Effect-Bioavailability-and-Fed-Bioequivalence-Studies.pdf. Accessed 18 Jan 2022."},{"key":"770_CR18","doi-asserted-by":"crossref","unstructured":"Deng J, Zhu X, Chen Z, Fan CH, Kwan HS, Wong CH, Shek KY, Zuo Z, Lam TN. A review of food\u2013drug interactions on oral drug absorption. Drugs. 2017;77(17):1833\u201355.","DOI":"10.1007\/s40265-017-0832-z"},{"issue":"3","key":"770_CR19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1365-2125.1980.tb01763.x","volume":"10","author":"CA Naranjo","year":"1980","unstructured":"Naranjo CA, Sellers EM, Khouw V. Fatty acids modulation of meal-induced variations in diazepam free fraction. Br J Clin Pharmacol. 1980;10(3):308\u201310.","journal-title":"Br J Clin Pharmacol"},{"key":"770_CR20","unstructured":"Bayer HealthCare Pharmaceuticals Inc. Kerendia (finerenone) tablets, for oral use: US prescribing information. 2021. https:\/\/labeling.bayerhealthcare.com. Accessed 18 Jan 2022."},{"key":"770_CR21","doi-asserted-by":"crossref","unstructured":"Giannini EG, Crespi M, Djahandideh A, Demarzo MG, Moscatelli A, Bodini G, Furnari M, Marabotto E, Plaz Torres MC, Zentilin P, Savarino V. Appropriateness of proton pump inhibitors treatment in clinical practice: prospective evaluation in outpatients and perspective assessment of drug optimisation. Dig Liver Dis. 2020;52(8):862\u20138.","DOI":"10.1016\/j.dld.2020.05.005"},{"key":"770_CR22","unstructured":"US Department of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research (CDER). Guidance for industry. Evaluation of gastric pH-dependent drug interactions with acid-reducing agents: study design, data analysis, and clinical implications, November 2020. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/evaluation-gastric-ph-dependent-drug-interactions-acid-reducing-agents-study-design-data-analysis. Accessed 18 Jan 2022."},{"issue":"2","key":"770_CR23","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S0016-5085(76)80200-4","volume":"71","author":"A Hurwitz","year":"1976","unstructured":"Hurwitz A, Robinson RG, Vats TS, Whittier FC, Herrin WF. Effects of antacids on gastric emptying. Gastroenterology. 1976;71(2):268\u201373.","journal-title":"Gastroenterology"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00770-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-022-00770-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-022-00770-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T03:38:52Z","timestamp":1656128332000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-022-00770-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1007\/s13318-022-00770-z","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"assertion":[{"value":"22 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by Bayer AG, Wuppertal, Germany. Editorial support, including fact checking, referencing, figure preparation, formatting, proofreading, and submission was provided by Evangelia Giannakouri, PhD, and Ian Norton, PhD, of Scion, London, UK, supported by Bayer AG, Wuppertal, Germany, according to Good Publication Practice guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RH and JN are employees of Bayer AG. SL is an employee of Chrestos Concept GmbH & Co. KG, which received funding for this analysis from Bayer AG. In addition, RH and JN have stock in Bayer AG, but are not paid in stock or stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures in this study were in accordance with the 1964 Declaration of Helsinki (and its amendments). This article does not contain any studies with animals performed by any of the authors. All study protocols were reviewed and approved by the ethics committee of the respective medical council (D\u00fcsseldorf [studies 1 and 3] and Berlin [study 2], Germany) and by the Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte (The Federal Institute for Drugs and Medical Devices), Bonn, Germany.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies before study commencement.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Availability of the data underlying this publication will be determined later according to Bayer\u2019s commitment to the EFPIA\/PhRMA principles for responsible clinical trial data sharing. This pertains to scope, time point and process of data access. As such, Bayer commits to sharing, upon request from qualified scientific and medical researchers, participant-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in participants for medicines and indications approved in the United States (US) and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 1, 2014. Interested researchers can use  to request access to anonymized participant-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the study sponsor\u2019s section of the portal. Data access will be granted to anonymized participant-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that participant privacy is safeguarded.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"RH, JN, and SL participated in the study concept and design and were involved in the acquisition, analysis, and interpretation of the respective data. All authors participated in preparing and approving the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}